Safety and Tolerability Evaluation Study of BVAC-B in Patients With HER2/Neu(Human Epithelial Growth Factor Receptor 2) Positive Gastric Cancer After Failure to Standard Care
PHASE1CompletedINTERVENTIONAL
Enrollment
8
Participants
Timeline
Start Date
February 26, 2018
Primary Completion Date
May 13, 2019
Study Completion Date
May 13, 2019
Conditions
Stomach Neoplasms
Interventions
BIOLOGICAL
BVAC-B
Autologous B cell and monocyte presenting HER2/neu antigen
Trial Locations (1)
03722
Severance Hospital, Seoul
All Listed Sponsors
lead
Cellid Co., Ltd.
INDUSTRY
NCT03425773 - Safety and Tolerability Evaluation Study of BVAC-B in Patients With HER2/Neu(Human Epithelial Growth Factor Receptor 2) Positive Gastric Cancer After Failure to Standard Care | Biotech Hunter | Biotech Hunter